Hisilicon: It is expected that the net profit in the first quarter of 2026 will increase by 923.34% - 1094.97% compared to the same period.

Hisilicon announced that it is expected to have a net profit of 477 million to 557 million yuan in the first quarter of 2026, a year-on-year growth of 923.34% - 1094.97%. The company is actively expanding its market and continuing to achieve good growth in innovative drug sales. In addition, in January 2026, the company transferred the overseas development, production, and commercialization rights of HSK39004 to AirNexis Therapeutics, Inc. for an initial payment of 108 million US dollars and additional milestone payments of up to 955 million US dollars, along with royalty fees. During the reporting period, the company received all of the above-mentioned initial payment in cash and part of the equity and recognized revenue. Therefore, despite the high growth in research and development expenses, the net profit attributable to the shareholders of the listed company and the net profit after deducting non-recurring gains and losses still achieved high growth.